World Markets Ophthalmology

In a market dominated by the entry of Lucentis and off-label Avastin on the one hand and generic competition on the other, it is challenging to navigate the landscape of the ophthalmology industry.

World Markets Ophthalmology provides you with the tools and insight you need to successfully navigate this evolving market.

Features:

• The Ophtha-Online Database provides coverage of over 500 drugs, both approved and under development, for 12 diseases 
• Up to 55 sets of data per drug, from Phase I through to approval including: 
  • Pricing and Reimbursement 
  • Research and Development 
  • Disease Area 
  • Corporate: licensing, patent and strategic-planning information 
• Same-day Analysis of all key news and events related to the ophthalmology market. 
• Monthly Ophthalmology Milestones Bulletin, which providing editorial analysis of database updates

Benefits:

• Understand how approvals and reimbursement were secured or not secured, based on clinical endpoints, design and results, as well as pricing 
• Compare and break down the cost of drugs per day of treatment in each of the major disease areas 
• Understand the key market access barriers to new ophthalmology drugs, including clinical guidelines, special authority restrictions and detailed overviews of cost-effectiveness calculations and reimbursement decisions 
• Find new licensing opportunities and key areas of research and development 
• Assess the risk posed by drugs under development based on disease, drug class and manufacturer

Who should use World Markets Ophthalmology?

• Strategic planners 
• Pricing managers 
• Business development managers 
• Competitive intelligence managers 
• Research associates 
• Regulatory executives

The Ophtha-Online Database:

Coverage of over 500 drugs, both approved and under development, for 12 diseases in the ophthalmology market, including:

• Glaucoma 
• Intraocular Pressure and Ocular Hypertension 
• Macular Degeneration 
• Diabetic Macular Edema 
• Conjunctivitis (bacterial, allergic and all other forms) 
• Eye Infections (bacterial, viral and fungal) 
• Dry Eyes 
• Uveitis 
• Retinal Vessel Occlusion 
• Ocular Surface Disease 
• Retinitis Pigmentosa 
• Fungal Keratitis

The database also includes global pipelines and pricing, reimbursement, approval and cost information for medicines in France, Germany, Italy, Japan, Spain, the United Kingdom and the United States.

Up to 55 sets of data per drug, from Phase I through approval, including:

• Pricing and Reimbursement: 
  • Average cost per drug per day in each of the disease areas for any marketed drug, taking into account the price, dosing, average duration of use and presentation 
  • Ex-manufacturing prices, reimbursement restrictions, and guidelines 
  • Analysis of the average level of cost outside the reibursement structure
• Research and Development: 
  • Clinical trial design, endpoints, results and forward-looking approval information
• Disease Area: 
  • Drug classes, product concentration in each drug class and disease landscape
• Corporate: 
  • Licensing, patent and strategic-planning information
• Same-day Analysis and Profiles:
  • Same-day Analysis of all key news and events related to the ophthalmology market
• Monthly Ophthalmology Milestones bulletin, summarizing updates to the database and provides editorial analysis.

Our expert team provides an independent, fact-based view of the healthcare and pharmaceutical industry, fully supported by our 325+ economists and analysts worldwide with expertise in over 120 industries and 200 countries.

IHS Global Insight is the world leader in economic and financial analysis, forecasting and market intelligence, with more than 40 years experience and an outstanding record for accuracy.